News

15th Invitation to manufacturers of antituberculosis medicines to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team: medicines (14 November 2017)

Revision to EOI:

1. Under heading "3. Single ingredient second-line anti-tuberculosis medicines", adding the indication "(scored)" to the existing following item:

  • Moxifloxacin, tablet/capsule 400 mg (scored)

 

2. Under heading "5. Solid dosage formulations for children, in single dose format", adding the indication "(scored and dispersible)" to the existing following items:

  • Ethambutol tablet 100 mg (scored and dispersible); 50 mg (scored and dispersible)
  • Isoniazid tablet 100 mg (scored and dispersible); 50 mg (scored and dispersible)
  • Pyrazinamide tablet 150 mg (scored and dispersible)
  • Cycloserine capsule 125 mg (scored and dispersible)
  • Levofloxacin tablet 100 mg (scored and dispersible)
  • Moxifloxacin tablet 100 mg (scored and dispersible)
  • Linezolid tablet 150 mg (scored and dispersible)
  • Ethionamide tablet 125 mg (scored and dispersible)